Drugs / BIIB105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04494256 | Sep 2020 → Aug 2024 | amyotrophic lateral sclerosis | Biogen | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-05-16 | Ionis Pharmaceuticals | Results Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis ionis.com ↗ |
| 2024-05-16 | Biogen | Results Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis biogen.com ↗
However, over the 6-month placebo-controlled period, treatment with BIIB105 did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-16 | Ionis Pharmaceuticals | Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis ionis.com ↗ |
| 2024-05-16 | Biogen | Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis biogen.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04494256 ↗ |
| Action | Inhibit | “BIIB105 is an investigational drug designed to reduce the levels of a protein called ATXN2.” NCT04494256 ↗ |
| Route | Intrathecal | “It is administered intrathecally (via a procedure called lumbar puncture).” NCT04494256 ↗ |
| Target | ATXN2 | “BIIB105 is an investigational drug designed to reduce the levels of a protein called ATXN2.” NCT04494256 ↗ |